Cetilistat

Source: Wikipedia, the free encyclopedia.
Cetilistat
Clinical data
ATC code
  • none
Identifiers
  • 2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one
JSmol)
  • CCCCCCCCCCCCCCCCOc2oc(=O)c1cc(C)ccc1n2
  • InChI=1S/C25H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-28-25-26-23-18-17-21(2)20-22(23)24(27)29-25/h17-18,20H,3-16,19H2,1-2H3 ☒N
  • Key:MVCQKIKWYUURMU-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Cetilistat is a drug designed to treat

intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested.[1]

In human trials from 2007, cetilistat was shown to produce similar weight loss to orlistat, but also produced similar side effects such as oily, loose stools,

fat-soluble vitamins
and other fat-soluble nutrients may be inhibited, requiring vitamin supplements to be used to avoid deficiencies.

Cetilistat completed Phase 1 and 2 trials in the West and as of 2009 was in Phase 3 trials in Japan where it was partnered with Takeda.[4] Norgine BV acquired the full global rights to cetilistat from Alizyme after the latter went into administration.[5][needs update]

In 2010, a phase 2 trial found cetilistat significantly reduced weight and was better tolerated than orlistat.[6]

Takeda gained approval to market Cetilistat in Japan, but terminated the license agreement with Norgine in 2018. [7]

See also

References

  1. S2CID 29076657
    .
  2. PMID 16953261
    .
  3. PMID 18393108
    .
  4. ^ "Alizyme - Cetilistat". www.alizyme.com. Archived from the original on January 7, 2009.
  5. ^ "Norgine acquires cetilistat" (PDF). Archived from the original (PDF) on 2011-01-24. Retrieved 2010-02-10.
  6. PMID 19461584
    .
  7. ^ "Takeda and Norgine terminate obesity drug deal". Retrieved 2021-01-18.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Cetilistat&oldid=1188075263"